S&P 500   4,122.47
DOW   32,774.41
QQQ   317.08
Are Medtronic And Intuitive Surgical Poised For Big Growth?
Copper More Critical than Lithium? (Ad)
'The Sacrifice Zone': Myanmar bears cost of green energy
Is Sofi Financial Stock Finally Ready to Pay Off for Investors?
Ralph Lauren Is A Retail Stock You Can Buy And Hold
Investor Alert: Argentina Loaded With "White Gold" Opportunity (Ad)
Closing prices for crude oil, gold and other commodities
Learning from failures: How Biden scored win on climate plan
Most electric vehicles won't qualify for federal tax credit
Copper More Critical than Lithium? (Ad)
S&P 500   4,122.47
DOW   32,774.41
QQQ   317.08
Are Medtronic And Intuitive Surgical Poised For Big Growth?
Copper More Critical than Lithium? (Ad)
'The Sacrifice Zone': Myanmar bears cost of green energy
Is Sofi Financial Stock Finally Ready to Pay Off for Investors?
Ralph Lauren Is A Retail Stock You Can Buy And Hold
Investor Alert: Argentina Loaded With "White Gold" Opportunity (Ad)
Closing prices for crude oil, gold and other commodities
Learning from failures: How Biden scored win on climate plan
Most electric vehicles won't qualify for federal tax credit
Copper More Critical than Lithium? (Ad)
S&P 500   4,122.47
DOW   32,774.41
QQQ   317.08
Are Medtronic And Intuitive Surgical Poised For Big Growth?
Copper More Critical than Lithium? (Ad)
'The Sacrifice Zone': Myanmar bears cost of green energy
Is Sofi Financial Stock Finally Ready to Pay Off for Investors?
Ralph Lauren Is A Retail Stock You Can Buy And Hold
Investor Alert: Argentina Loaded With "White Gold" Opportunity (Ad)
Closing prices for crude oil, gold and other commodities
Learning from failures: How Biden scored win on climate plan
Most electric vehicles won't qualify for federal tax credit
Copper More Critical than Lithium? (Ad)
S&P 500   4,122.47
DOW   32,774.41
QQQ   317.08
Are Medtronic And Intuitive Surgical Poised For Big Growth?
Copper More Critical than Lithium? (Ad)
'The Sacrifice Zone': Myanmar bears cost of green energy
Is Sofi Financial Stock Finally Ready to Pay Off for Investors?
Ralph Lauren Is A Retail Stock You Can Buy And Hold
Investor Alert: Argentina Loaded With "White Gold" Opportunity (Ad)
Closing prices for crude oil, gold and other commodities
Learning from failures: How Biden scored win on climate plan
Most electric vehicles won't qualify for federal tax credit
Copper More Critical than Lithium? (Ad)
NASDAQ:VCYT

Veracyte - VCYT Stock Forecast, Price & News

$24.13
-2.70 (-10.06%)
(As of 08/9/2022 12:00 AM ET)
Add
Compare
Today's Range
$23.48
$26.38
50-Day Range
$15.96
$27.90
52-Week Range
$14.85
$54.13
Volume
916,558 shs
Average Volume
953,496 shs
Market Capitalization
$1.73 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$42.50

Veracyte MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
76.1% Upside
$42.50 Price Target
Short Interest
Bearish
12.17% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.05
Upright™ Environmental Score
News Sentiment
0.22mentions of Veracyte in the last 14 days
Based on 20 Articles This Week
Insider Trading
Acquiring Shares
$979,800 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($0.82) to ($0.56) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.21 out of 5 stars

Medical Sector

434th out of 1,098 stocks

Medical Laboratories Industry

15th out of 27 stocks

VCYT stock logo

About Veracyte (NASDAQ:VCYT) Stock

Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Genomic Sequencing Classifier and Percepta Nasal Swab Test for lung cancer diagnosis; Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis; and Immunoscore Colon Cancer test for colon cancer diagnosis. It is also developing Percepta Genomic Atlas to help inform lung cancer treatment decisions; Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test. Veracyte, Inc. has technology licensing and collaboration arrangements with Johnson & Johnson; Acerta Pharma; and CareDx. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.

Analyst Ratings Changes

Several equities analysts recently weighed in on VCYT shares. Needham & Company LLC raised their target price on shares of Veracyte from $26.00 to $31.00 and gave the company a "buy" rating in a research note on Wednesday, August 3rd. Raymond James raised their price target on Veracyte from $30.00 to $31.00 and gave the company an "outperform" rating in a report on Thursday, August 4th. One research analyst has rated the stock with a sell rating and six have assigned a buy rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $42.50.

Veracyte Price Performance

Veracyte stock traded down $2.70 during mid-day trading on Tuesday, hitting $24.13. 916,558 shares of the company's stock traded hands, compared to its average volume of 953,496. Veracyte has a fifty-two week low of $14.85 and a fifty-two week high of $54.13. The stock has a market cap of $1.73 billion, a price-to-earnings ratio of -35.48 and a beta of 1.10. The firm has a 50 day simple moving average of $22.27 and a two-hundred day simple moving average of $23.76.

Insider Transactions at Veracyte

In other news, Director Jens Holstein sold 8,720 shares of Veracyte stock in a transaction on Tuesday, June 14th. The stock was sold at an average price of $16.27, for a total transaction of $141,874.40. Following the completion of the sale, the director now owns 2,000 shares of the company's stock, valued at $32,540. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In other news, CEO Marc Stapley bought 60,000 shares of the company's stock in a transaction dated Friday, June 10th. The stock was bought at an average price of $16.33 per share, with a total value of $979,800.00. Following the completion of the acquisition, the chief executive officer now owns 159,761 shares of the company's stock, valued at $2,608,897.13. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Jens Holstein sold 8,720 shares of Veracyte stock in a transaction on Tuesday, June 14th. The stock was sold at an average price of $16.27, for a total value of $141,874.40. Following the sale, the director now directly owns 2,000 shares of the company's stock, valued at approximately $32,540. The disclosure for this sale can be found here. Insiders own 2.90% of the company's stock.

Receive VCYT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Veracyte and its competitors with MarketBeat's FREE daily newsletter.

VCYT Stock News Headlines

Veracyte: Q2 Earnings Insights - Benzinga
Veracyte's Earnings: A Preview - Benzinga
Veracyte's Earnings: A Preview
Veracyte (VCYT) to Release Quarterly Earnings on Tuesday
See More Headlines
Receive VCYT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Veracyte and its competitors with MarketBeat's FREE daily newsletter.

VCYT Company Calendar

Last Earnings
11/09/2021
Today
8/10/2022
Next Earnings (Estimated)
11/08/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Medical laboratories
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:VCYT
Employees
761
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$42.50
High Stock Price Forecast
$59.00
Low Stock Price Forecast
$31.00
Forecasted Upside/Downside
+76.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
6 Analysts

Profitability

Net Income
$-75,560,000.00
Pretax Margin
-18.97%

Debt

Sales & Book Value

Annual Sales
$219.51 million
Book Value
$15.43 per share

Miscellaneous

Free Float
69,500,000
Market Cap
$1.73 billion
Optionable
Optionable
Beta
1.10

Key Executives

  • Ms. Bonnie H. Anderson (Age 64)
    Co-Founder & Exec. Chairwoman
    Comp: $1.21M
  • Mr. Marc A. Stapley (Age 52)
    CEO & Director
    Comp: $900.4k
  • Ms. Rebecca Chambers (Age 44)
    Exec. VP & CFO
    Comp: $607.65k
  • Dr. Giulia C. Kennedy Ph.D. (Age 63)
    Global Chief Scientific Officer & Chief Medical Officer
    Comp: $691.33k
  • Dr. Tina S. Nova Ph.D. (Age 68)
    Pres of CLIA U.S. Bus.
    Comp: $4.58k
  • Ms. Beverly Jane Alley CPA (Age 59)
    VP & Corp. Controller
    Comp: $398.01k
  • Mr. Jonathan Wygant (Age 51)
    VP & Chief Accounting Officer
  • Ms. Annie McGuire (Age 42)
    Sr. VP & Gen. Counsel
  • Ms. Tracy Morris
    VP of Global Corp. Communications
  • Mr. John Walter Hanna Jr. (Age 41)
    Chief Commercial Officer and GM of Endocrinology, Breast Cancer & Lymphoma













VCYT Stock - Frequently Asked Questions

Should I buy or sell Veracyte stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Veracyte in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" VCYT shares.
View VCYT analyst ratings
or view top-rated stocks.

What is Veracyte's stock price forecast for 2022?

6 brokers have issued 1-year price objectives for Veracyte's stock. Their VCYT share price forecasts range from $31.00 to $59.00. On average, they predict the company's share price to reach $42.50 in the next twelve months. This suggests a possible upside of 76.1% from the stock's current price.
View analysts price targets for VCYT
or view top-rated stocks among Wall Street analysts.

How has Veracyte's stock performed in 2022?

Veracyte's stock was trading at $41.20 on January 1st, 2022. Since then, VCYT stock has decreased by 41.4% and is now trading at $24.13.
View the best growth stocks for 2022 here
.

When is Veracyte's next earnings date?

Veracyte is scheduled to release its next quarterly earnings announcement on Tuesday, November 8th 2022.
View our VCYT earnings forecast
.

How were Veracyte's earnings last quarter?

Veracyte, Inc. (NASDAQ:VCYT) issued its quarterly earnings data on Tuesday, November, 9th. The biotechnology company reported ($0.20) earnings per share for the quarter, missing the consensus estimate of ($0.14) by $0.06. The biotechnology company had revenue of $60.37 million for the quarter, compared to analysts' expectations of $54.66 million. Veracyte had a negative net margin of 18.13% and a negative trailing twelve-month return on equity of 4.05%. During the same quarter in the prior year, the business posted ($0.08) EPS.

What guidance has Veracyte issued on next quarter's earnings?

Veracyte updated its FY 2022 earnings guidance on Tuesday, August, 9th. The company provided EPS guidance of for the period. The company issued revenue guidance of $272.00 million-$280.00 million, compared to the consensus revenue estimate of $272.42 million.

What other stocks do shareholders of Veracyte own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Veracyte investors own include Hawkins (HWKN), Invitae (NVTA), AbbVie (ABBV), CA (CA), CRISPR Therapeutics (CRSP), Advanced Micro Devices (AMD), Editas Medicine (EDIT), NVIDIA (NVDA), Exelixis (EXEL) and NeoGenomics (NEO).

What is Veracyte's stock symbol?

Veracyte trades on the NASDAQ under the ticker symbol "VCYT."

Who are Veracyte's major shareholders?

Veracyte's stock is owned by many different institutional and retail investors. Top institutional shareholders include ARK Investment Management LLC (12.40%), Sumitomo Mitsui Trust Holdings Inc. (4.09%), Nikko Asset Management Americas Inc. (4.09%), Pictet Asset Management SA (2.02%), Silverarc Capital Management LLC (1.01%) and AEGON ASSET MANAGEMENT UK Plc (0.61%). Insiders that own company stock include Bonnie H Anderson, Evan/ Fa Jones, Giulia C Kennedy, Giulia C Kennedy, Jens Holstein, John Walter Hanna Jr, John Walter Hanna, Jr, Karin Eastham, Keith Kennedy, Kevin K Gordon, Marc Stapley, Mark Ho and Robert S Epstein.
View institutional ownership trends
.

How do I buy shares of Veracyte?

Shares of VCYT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Veracyte's stock price today?

One share of VCYT stock can currently be purchased for approximately $24.13.

How much money does Veracyte make?

Veracyte (NASDAQ:VCYT) has a market capitalization of $1.73 billion and generates $219.51 million in revenue each year. The biotechnology company earns $-75,560,000.00 in net income (profit) each year or ($0.68) on an earnings per share basis.

How many employees does Veracyte have?

Veracyte employs 761 workers across the globe.

How can I contact Veracyte?

Veracyte's mailing address is 6000 SHORELINE COURT SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.veracyte.com. The biotechnology company can be reached via phone at (650) 243-6300, via email at keith@veracyte.com, or via fax at 650-243-6301.

This page (NASDAQ:VCYT) was last updated on 8/10/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.